 |
BukwangBukwang Pharm. Co. (www.bukwang.co.kr), Ltd. is a leading Korean pharmaceutical company listed on the Korean Stock Exchange [KRX:003000]. The company has been in business for over 50 years, and achieved US$150 million in sales in 2020. Sales are primarily derived from products licensed from Europe, the United States, and Japan. The company is currently investing significant resources in R&D to create a robust pipeline of preclinical and clinical agents for the treatment of antiviral diseases, gastrointestinal disorders, CNS disorders and metabolic disease. Bukwang is our partner for JM-010. |
 |
Medici InvestmentMedici Investment is one of the most prestigious VCs and PEs in Korea. They have invested in many companies within various areas; especially, Medici is recognized for investments in biotech companies, ever since their inception in 2011. In addition, Medici is well known VC as an outstanding GP of many blind funds built and managed in Korea. Medici´s total invested assets are around USD 1.1B and it has recorded the best financial profit rate among all venture capitals in Korea. |
Recent News
September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more
Contact us
Contera Pharma Headquarter
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
